The pharmaceutical and medical technology sector in WA has launched an industry association, more than one year after the state government promised its own growth plan for the industry.
ASX-listed clinical-stage oncology company, PharmAust has pocketed $755,594 after the ATO accepted its application for a Research and Development rebate in recognition of the innovations under development by the company's wholly owned subsidiaries, Epichem and Pitney Pharmaceuticals. PharmAust said it plans to plough the cash straight back into ongoing clinical trials of its therapeutics on humans and animals.
ASX-listed PharmAust subsidiary, Epichem, has entered into a multi-year license agreement to harness “Oxidative Hydrothermal Dissolution” technology from IP owner, Illinois-based Thermaquatica. Epichem will research, develop and promote Thermaquatica's disruptive waste to fuels technology that uses waste and biomass as a feedstock. The company will also target government grant funding to accelerate its research and development initiative.
PharmAust subsidiary Epichem has significantly revised its forecast revenue following the announcement one of its major customers would end its contract with the company next month.
Our daily board moves wrap includes Tim Mason, Charlie Bass, Tim Staermose, Colin La Galia, Martine Keenan, Paul Goldfinch, Simon Mitchell, Ashley Hood, and Ian Macliver.
Claremont-based biotech company PharmAust has announced a record year for its synthetic and medicinal chemistry subsidiary, and has flagged further growth in the year ahead.
Epichem, a wholly owned subsidiary of ASX listed biotech hopeful Pharmaust, has reached the pinnacle of its 13 year existence with the opening of its new state of the art chemistry lab in Technology Park, Bentley. The new lab which is double the size of the old one previously operated on site at Murdoch University, cost $1.6m and boasts a serious brains trust of 13 PHD's amongst its 18 staff.
FRUIT and dairy producer Harvey Fresh has topped the field in the state's annual industry and export awards.Harvey Fresh took out the Premier's award for excellence.
PharmAust Ltd’s wholly owned subsidiary Epichem Pty Ltd has secured its largest single contract to date, a $3 million agreement with Swiss-based Drugs for Neglected Diseases initiative.
